DIPLOIDE is a global bioscience and genetic services company, that develops customized genetic services to provide actionable bioinformatics that improves health of individuals more assertively. DIPLOIDE has created the first market for integrated genetic testing in South America, where individuals, health professionals and health service providers can explore various products and services applied to precision medicine for proactive health, reproductive health, clinical diagnosis and translational clinics. DIPLOIDE is headquartered in Washington DC and operates laboratories with one of the largest next-generation sequencing capacity in the world with facilities in Toronto, Canada, Brighton, England, University of California Davis Campus, University of Toronto, University of Cambridge, Estonia , and Beijing, China which is accredited by the Federal Drug Administration (FDA), the Clinical Laboratory Improvement Amendments (CLIA) and the Faculty of American Pathologists (CAP). DIPLOIDE GENETICS INC. started operations in 2018 and in April 2019 DIPLOIDE GENETICS SAS is incorporated in Colombia to develop the whole LATAM market for NGS and LIFE SCIENCE RESEARCH TECHNOLOGIES joining research efforts with strategic academic and institutional partners, linked to the health sector.